Hanmi Pharmaceutical shares were strong in early trading on the 23rd. Buying appears to have gathered on news that it announced research results for a new drug that reduces the muscle loss side effect of existing obesity treatments.
As of 9:22 a.m. that day, Hanmi Pharmaceutical was trading at 395,500 won, up 29,500 won (8.06%) from the previous session. It rose to as high as 414,000 won during the session, hitting a 1-year high.
That day, Hanmi Pharmaceutical said it presented six preclinical study results for three new obesity drugs—the next-generation obesity therapy (LA-UCN2) HM17321, the next-generation triple-agonist obesity therapy (LA-GLP·GIP·GCG) "HM15275," and the oral obesity therapy "HM101460"—at the 61st European Association for the Study of Diabetes (EASD 2025), held in Vienna, Austria, from the 15th to the 19th.
Key presentations included: ▲ skeletal muscle proteomic analyses supporting HM17321's effects on muscle growth and metabolic improvement ▲ weight-loss efficacy of HM17321 in an obese nonhuman primate model and incretin combination efficacy in rodent models.
A Hanmi Pharmaceutical official said, "Aiming simultaneously for high-quality weight loss efficacy—fat reduction, muscle gain, and improvements in exercise and metabolic function—HM17321 is expected to establish itself as a first-in-class therapy in the field of treating metabolic diseases accompanied by obesity and muscle loss."